Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.580
-0.140 (-3.76%)
At close: Jul 31, 2026, 4:00 PM EDT
3.590
+0.010 (0.28%)
After-hours: Jul 31, 2026, 7:59 PM EDT
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Fulcrum Therapeutics stock has a consensus rating of "Hold" and an average price target of $5.83. The average 1-year stock price forecast is 62.85% higher than the current stock price, while the lowest is $3.00 (-16.20%) and the highest is $18 (+402.79%).
Price Target: $5.83 (+62.85%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Fulcrum Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 3 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Hold Maintains $4 | Hold | Maintains | $4 | +11.73% | Jul 31, 2026 |
| J.P. Morgan | J.P. Morgan | Sell Downgrades n/a | Sell | Downgrades | n/a | n/a | Jun 2, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Maintains $8 → $3 | Sell | Maintains | $8 → $3 | -16.20% | Jun 2, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades $25 → $3 | Hold | Downgrades | $25 → $3 | -16.20% | Jun 2, 2026 |
| Leerink Partners | Leerink Partners | Hold Downgrades $24 → $4 | Hold | Downgrades | $24 → $4 | +11.73% | Jun 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.76
from -1.18
EPS Next Year
-0.58
from -0.76
EPS and Forward PE are based on non-GAAP adjusted numbers.